Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Etoposide vs Apatinib in Platinum-Resistant Ovarian Cancer
NCT04383977Phase 2Unknown
- Sponsor
- Hengrui
- Start
- May 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Hengrui. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04383977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04383977.